Abstract:To the Editor We read with great interest the recent article entitled “Fluorescent‐ guided surgery for sentinel lymph node detection in gastric cancer and carcinoembryonic antigen targeted fluorescent‐guided surgery in colorectal and pancreatic cancer” by Vuijk et al. This study foresaw a bright future for tumor‐specific imaging and staging strategy. The rationale for carcinoembryonic antigen (CEA) targeted imaging lies in (a) CEA highly expressed on tumour types and it was unaffected by neoadjuvant therapy, (b) anti‐CEA chimerized monoclonal antibody conjugated fluorochrome outperformed normal fluorescent reagents by molecular structure and diagnostic efficiency, and (c) safe tolerability and pharmacokinetics. The author overviewed preclinical and clinical studies and emphasized that the CEA targeted fluorescence were able to demarcate tumor nodules that could not be visualized in conventional bright light surgery. However, a very high tumor‐to‐background ratio measured ex vivo vs in vivo, and a certain extent of autofluorescence and background scattering previously described in fluorescence imaging studies potentially hinted a need for more sensitive intraoperative imaging systems. For colorectal cancer: Serum CEA levels were reported to be inadequate for rectal cancer patient selection because of a lack of correlation between tumor CEA expression and serum CEA levels. Preoperative cT staging assessment has always been a suitable and valid standard of patient selection. For pancreatic cancer: Disadvantageous CEA loss expression after neoadjuvant treatment was seen in pancreatic ductal adenocarcinoma. Serum CEA levels seem to be accurate to predict CEA tumor expression for fluorescence imaging surgery and posthospital follow up without a history of neoadjuvant treatment. For gastric cancer: Complicated lymphatic drainage and completely obliterated lymph channels (or nodes) have always been challenging for fluorescence imaging using indocyanine green (ICG) or ICG:NanoColl, underlining an urgent need for tumor‐specific fluorescent tracers for gastric cancer. The author foresaw a bright future for tumor‐specific imaging for gastric cancer. Whereas, the author was not sure if there exists a tumor‐targeted reagent that will wondrously outmatch pathological detection. In addition, what we especially want to propose is that a fluorescence imaging is just a macroscopic optical imaging, although it is combined with tumor‐specific regents in molecular level. To date, pathological testing remains a gold reference to discriminate cytological malignancy. Pathology molecular diagnostic techniques, such as reverse transcription‐polymerase chain reaction and one‐step nucleic acid amplification, have emerged as rapid, real‐time, and sensitive tools to detect lymph node micrometastasis. However, the time required to obtain results is still too long for use in the intraoperative diagnosis, and more studies are needed to improve these molecular tools. Therefore, future perspectives and expectations should look forward to tumor specific fluorescence imaging and these evolving and innovative pathological diagnosis techniques as well.

Multimodality PET and Near-Infrared Fluorescence Intraoperative Imaging of CEA-Positive Colorectal Cancer

Early Tumor Detection Afforded by in Vivo Imaging of Near-Infrared Ii Fluorescence

Novel Dual-Function Near-Infrared II Fluorescence and PET Probe for Tumor Delineation and Image-Guided Surgery.

Detection of Micrometastases Using SPECT/Fluorescence Dual-Modality Imaging in a CEA-Expressing Tumor Model

PET/NIR Fluorescence Bimodal Imaging for Targeted Tumor Detection

NIR-II fluorescence imaging-guided colorectal cancer surgery targeting CEACAM5 by a nanobody

Excessive Expectations for Carcinoembryonic Antigen Targeted Fluorescent‐guided Surgery for Sentinel Lymph Node Detection in Colorectal, Pancreatic, and Gastric Cancer

Multimodal CEA-targeted fluorescence and radioguided cytoreductive surgery for peritoneal metastases of colorectal origin

Evaluation of the tumor-targeting specific imaging and killing effect of a CEA-targeting nanoparticle in colorectal cancer

Rapid tumor‐labeling kinetics with a site‐specific near‐infrared anti‐CEA nanobody in a patient‐derived orthotopic xenograft mouse model of colon cancer

A Dual Reporter Iodinated Labeling Reagent for Cancer Positron Emission Tomography Imaging and Fluorescence-Guided Surgery

Targeted Biodegradable Near-Infrared Fluorescent Nanoparticles for Colorectal Cancer Imaging

Extracellular vesicles-based pre-targeting strategy enables multi-modal imaging of orthotopic colon cancer and image-guided surgery

ImmunoPET and Near-Infrared Fluorescence Imaging of CD105 Expression Using a Monoclonal Antibody Dual-Labeled with (89)zr and IRDye 800CW.

High-precision detection and navigation surgery of colorectal cancer micrometastases

Photoactive imaging and therapy for colorectal cancer using a CEA-Affimer conjugated Foslip nanoparticle

A pan-cancer agent for screening, resection and wound monitoring via NIR and SWIR imaging

Multimodality Imaging Of Breast Cancer Experimental Lung Metastasis With Bioluminescence And A Monoclonal Antibody Dual-Labeled With Zr-89 And Irdye 800cw

A pilot study of near-infrared fluorescence guided surgery for primary tumor localization and lymph node mapping in colorectal cancer

A Concept for Preoperative and Intraoperative Molecular Imaging and Detection for Assessing Extent of Disease of Solid Tumors

Intraperitoneal Injection of Cyanine-Based Nanomicelles for Enhanced Near-Infrared Fluorescence Imaging and Surgical Navigation in Abdominal Tumors